Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Por Neu, H C, Meropol, N J, Fu, K P
Publicado em 1981

Patient–physician discordance in goals of care for patients with advanced cancer

Por Douglas, S.L., Daly, B.J., Meropol, N.J., Lipson, A.R.
Publicado no Curr Oncol (2019)

Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods.

Por Mandelblatt, J S, Bierman, A S, Gold, K, Zhang, Y, Ng, J H, Maserejan, N, Hwang, Y T, Meropol, N J, Hadley, J, Silliman, R A
Publicado em 2001

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer

Por Dotan, E, Meropol, N J, Zhu, F, Zambito, F, Bove, B, Cai, K Q, Godwin, A K, Golemis, E A, Astsaturov, I, Cohen, S J
Publicado em 2012

Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer

Por Cohen, S J, Konski, A A, Putnam, S, Ball, D S, Meyer, J E, Yu, J Q, Astsaturov, I, Marlow, C, Dickens, A, Cade, D N, Meropol, N J
Publicado em 2014

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

Por Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Publicado no Br J Cancer (2015)

Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers

Por MANNE, S., KASHY, D., ALBRECHT, T., WONG, Y.-N., FLAMM, A. LEDERMAN, BENSON, A. B., MILLER, S.M., FLEISHER, LINDA, BUZAGLO, J., ROACH, N., KATZ, M., ROSS, E., COLLINS, M., POOLE, D., RAIVITCH, S., MILLER, D.M., KINZY, T.G., LIU, T., MEROPOL, N.J.
Publicado no Eur J Cancer Care (Engl) (2014)